| 摘要: |
| Status and progress of pulmonary drug delivery systems in the treatment of lung infections |
| 关键词: 抗菌药物 细菌耐药 铜绿假单胞菌 吸入制剂 药物递送系统 |
| DOI:10.13506/j.cnki.jpr.2020.11.010 |
| 基金项目:国家自然科学基金(No.81903565);天津市自然科学基金项目(No.18JCQNJC13500) |
|
出版日期:2020-11-25
|
|
| 近年来,社区获得性肺炎成为最为常见的肺部感染,发病群体极为广泛,造成严重的健康威胁。本文对抗菌药物细菌耐药性、药物递送系统(DDS)在肺部感染治疗方面的优势和研究难点等研究进行归纳和总结,简要介绍了抗菌药物在肺部治疗的现状,针对肺部感染的药物递送,特别是针对铜绿假单胞菌(PA)感染,讨论了目前肺部递送抗菌药物载体的研究进展及DDS与肺部生物屏障的相互作用,以期为解决抗菌药物治疗方面面临的重大问题和克服肺部生物学屏障、提高药物在感染病灶的生物利用度提供一种新的思路。 |
|
| () |
| Abstract: |
| In recent years,community-acquired pneumonia has become the most common lung infection, with a very wide range of disease groups, posing a serious health threat. This article summarizes studies on antibacterial drug resistance, drug delivery system advantages and research difficulties in the treatment of lung infections, and briefly introduces the current status of antibacterial drugs in lung treatment.Drug delivery for lung infections, Especially for Pseudomonas aeruginosa (PA) infection, the current research progress of antibacterial drug delivery in the lungs and the interaction between DDS and the biological barrier of the lungs are discussed in order to solve the major problems faced by antibacterial drugs and overcome the lung It can provide a new way of thinking about the biological barrier and improve the bioavailability of drugs in infected lesions. |
| Key words: Antibacterial drugs Bacterial resistance Pseudomonas aeruginosa Inhaled preparation Drug delivery system |